A Phase 2b trial of elsiglutide, a peptide drug designed to prevent diarrhoea in patients undergoing chemotherapy, has failed to meet its primary endpoint even though there was some evidence of patient benefit. ---Subscribe to MedNous to access this article--- Company News Clinical Research
